NZ731591A - Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone - Google Patents

Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone

Info

Publication number
NZ731591A
NZ731591A NZ731591A NZ73159115A NZ731591A NZ 731591 A NZ731591 A NZ 731591A NZ 731591 A NZ731591 A NZ 731591A NZ 73159115 A NZ73159115 A NZ 73159115A NZ 731591 A NZ731591 A NZ 731591A
Authority
NZ
New Zealand
Prior art keywords
benzoic acid
oxycodone
conjugates
heteroaryl carboxylic
compound
Prior art date
Application number
NZ731591A
Other languages
English (en)
Inventor
Jaroslaw Kanski
Andrea K Martin
Sven Guenther
Bindu Bera
Sanjib Bera
Travis Mickle
Original Assignee
Kempharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kempharm Inc filed Critical Kempharm Inc
Publication of NZ731591A publication Critical patent/NZ731591A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D489/00Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C07D489/04Salts; Organic complexes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NZ731591A 2014-11-25 2015-11-25 Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone NZ731591A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462084216P 2014-11-25 2014-11-25
US201462084246P 2014-11-25 2014-11-25
PCT/US2015/062637 WO2016086113A1 (en) 2014-11-25 2015-11-25 Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone

Publications (1)

Publication Number Publication Date
NZ731591A true NZ731591A (en) 2018-06-29

Family

ID=56075034

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ731591A NZ731591A (en) 2014-11-25 2015-11-25 Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone

Country Status (18)

Country Link
US (3) US9850252B2 (https=)
EP (1) EP3223819A4 (https=)
JP (2) JP6400848B2 (https=)
KR (2) KR20190049944A (https=)
CN (1) CN106999486A (https=)
AU (1) AU2015353502B2 (https=)
BR (1) BR112017011069A2 (https=)
CA (1) CA2967424C (https=)
CL (1) CL2017001353A1 (https=)
CO (1) CO2017005201A2 (https=)
IL (1) IL252470B (https=)
MX (1) MX2017006520A (https=)
NZ (1) NZ731591A (https=)
PH (1) PH12017500963A1 (https=)
RU (1) RU2683317C2 (https=)
SG (1) SG11201704178UA (https=)
WO (1) WO2016086113A1 (https=)
ZA (1) ZA201703154B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA102916C2 (uk) 2009-07-02 2013-08-27 Кемфарм, Інк. Композиція на основі кон'югату гідрокодону з бензойною кислотою, похідними бензойної кислоти або гетероарилкарбоновою кислотою, проліки, спосіб лікування від зловживань
US10849981B2 (en) 2009-07-02 2020-12-01 KemPham, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
NZ731591A (en) 2014-11-25 2018-06-29 Kempharm Inc Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone
WO2018071879A1 (en) * 2016-10-14 2018-04-19 Kempharm, Inc. Immediate-release abuse deterrent compositions or medicaments for treating pain, add, adhd and other syndromes or disorders
WO2019018638A1 (en) * 2017-07-20 2019-01-24 Suzhou Runxindatai Pharmaceutics Ltd Co. PRODRUGS OF EXTENDED RELEASE OPIOID OPIOIDS RESISTANT TO ABUSE
EP3755704A1 (en) * 2018-02-23 2020-12-30 Rhodes Technologies Inc. Novel opioid compounds and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB320749A (https=)
US1731152A (en) 1925-10-27 1929-10-08 Firm C H Boehringer Sohn Process for the manufacture of derivatives of dihydrocodeinone or its substitution products
AT229496B (de) 1961-03-08 1963-09-25 Lannacher Heilmittel Verfahren zur Darstellung des neuen Nicotinsäureesters des Dihydrohydroxycodeinons
US4668685A (en) 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
SE9003665D0 (sv) 1990-11-16 1990-11-16 Kabivitrum Ab Morphine prodrugs
GB9423542D0 (en) 1994-11-22 1995-01-11 Marples Brian A Pharmaceutical compounds
US5869669A (en) * 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
IL150929A0 (en) 2000-01-28 2003-06-24 Rohm & Haas Pharmaceutical compounds comprising a pharmaceutically active moiety and a moiety comprising a substituent that enhances its properties
KR20040014544A (ko) 2001-06-05 2004-02-14 컨트롤 딜리버리 시스템즈 인코포레이티드 서방 진통제 화합물
US7375082B2 (en) 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
CA2477004C (en) 2002-02-22 2011-05-10 Thomas Piccariello Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
US20040058946A1 (en) 2002-07-05 2004-03-25 Buchwald Stephen L. Abuse-resistant prodrugs of oxycodone and other pharmaceuticals
TW200500067A (en) 2003-01-21 2005-01-01 Control Delivery Sys Inc Salts of codrugs and uses related thereto
JP2006520392A (ja) * 2003-03-13 2006-09-07 コントロールド・ケミカルズ・インコーポレーテッド 薬物の乱用可能性を低下させ且つ作用持続時間を延長する化合物および方法
EP1782834A3 (en) * 2003-03-13 2007-08-01 Controlled Chemicals, Inc. Oxycodone conjugates with lower abuse potential and extended duration of action
EP1675555A4 (en) 2003-09-30 2011-03-09 Shire Llc PHARMACEUTICAL COMPOSITIONS FOR PREVENTING EXCESSIVE DOSE OR ABUSE
CA2874604A1 (en) 2003-10-03 2005-04-21 Elite Laboratories Inc. Extended release formulations of opioids and method of use thereof
US20050203115A1 (en) * 2004-03-10 2005-09-15 Sancilio Frederick D. Narcotic-NSAID ion pairs
RU2365580C2 (ru) 2004-06-04 2009-08-27 Ксенопорт, Инк. Пролекарства леводопа, композиции на их основе и их применения
US7348430B2 (en) 2005-01-21 2008-03-25 Acura Pharmaceuticals, Inc. Production of opioid analgesics
AU2007238858A1 (en) * 2006-04-10 2007-10-25 Shire Llc Mono and di-substituted oxycodone compounds and compositions
CA2653741C (en) 2006-05-26 2015-07-07 Thomas E. Jenkins Controlled release of phenolic opioids
US20080090771A1 (en) 2006-10-06 2008-04-17 Shire Llc Abuse-resistant hydrocodone compounds, compositions and methods of using the same
ES2569655T3 (es) 2007-12-17 2016-05-12 Mallinckrodt Llc Procedimientos para la producción de compuestos de (+)-'nal' morfinano
EP2448408A4 (en) * 2009-07-02 2015-06-03 Kempharm Inc CONJUGATES OF PHENYLETHANOIC ACID, PHENYLPROPANOIC ACID AND PHENYLPROPENOIC ACID AND HYDROCODONE PRODRUGS, METHODS OF MAKING AND USING THEM
UA102916C2 (uk) * 2009-07-02 2013-08-27 Кемфарм, Інк. Композиція на основі кон'югату гідрокодону з бензойною кислотою, похідними бензойної кислоти або гетероарилкарбоновою кислотою, проліки, спосіб лікування від зловживань
US8623888B2 (en) 2009-07-15 2014-01-07 Mallinckrodt Llc 3-oxy-hydromorphone derivatives
ES2584634T3 (es) * 2011-01-11 2016-09-28 Signature Therapeutics, Inc. Composiciones que comprenden un profármaco de oxicodona escindible enzimáticamente
JP5769889B2 (ja) * 2011-10-26 2015-08-26 ケムファーム・インコーポレーテッド ヒドロモルホンの安息香酸、安息香酸誘導体及びヘテロアリールカルボン酸結合体、そのプロドラッグ、製造法及び使用
NZ731591A (en) 2014-11-25 2018-06-29 Kempharm Inc Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone

Also Published As

Publication number Publication date
JP6400848B2 (ja) 2018-10-03
KR101976101B1 (ko) 2019-05-09
AU2015353502A1 (en) 2017-05-25
RU2017122144A (ru) 2018-12-26
CO2017005201A2 (es) 2017-08-31
MX2017006520A (es) 2017-08-09
KR20170094249A (ko) 2017-08-17
US20180065975A1 (en) 2018-03-08
RU2017122144A3 (https=) 2018-12-26
EP3223819A4 (en) 2018-04-25
US10144740B2 (en) 2018-12-04
SG11201704178UA (en) 2017-06-29
ZA201703154B (en) 2019-03-27
CL2017001353A1 (es) 2018-01-05
IL252470B (en) 2019-08-29
WO2016086113A1 (en) 2016-06-02
PH12017500963A1 (en) 2017-10-18
JP2018199719A (ja) 2018-12-20
CA2967424A1 (en) 2016-06-02
RU2683317C2 (ru) 2019-03-28
BR112017011069A2 (pt) 2018-07-10
US20190048018A1 (en) 2019-02-14
EP3223819A1 (en) 2017-10-04
US9850252B2 (en) 2017-12-26
CA2967424C (en) 2023-05-02
US10544153B2 (en) 2020-01-28
JP2017535593A (ja) 2017-11-30
IL252470A0 (en) 2017-07-31
AU2015353502B2 (en) 2018-09-27
CN106999486A (zh) 2017-08-01
KR20190049944A (ko) 2019-05-09
US20160168160A1 (en) 2016-06-16

Similar Documents

Publication Publication Date Title
NZ731591A (en) Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
WO2013188783A8 (en) Deuterated derivatives of ruxolitinib
MX390302B (es) Oxiesteroles y metodos de uso de los mismos
WO2015095811A8 (en) Combination therapy with neoantigen vaccine
HK1244708A1 (zh) 作爲fxr/tgr5激动剂的胆汁酸类似物及其使用方法
PH12018500061A1 (en) Oxysterols and methods of use thereof
HK1255500A1 (zh) 氧固醇及其使用方法
NZ729037A (en) Carboxylic acid compound, method for preparation thereof, and use thereof
NZ704266A (en) Inhibitors of alpha-crystallin aggregation for the treatment for cataract
EP3412668A3 (en) A selective inhibitor of phosphatidylinositol 3-kinase-gamma
MX347105B (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona.
WO2013106761A3 (en) Antimicrobial agents
HK1220136A1 (zh) 治疗b2-缓激肽受体介导的血管性水肿的方法
PH12016500666A1 (en) Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
WO2014033526A9 (en) Pharmaceutical compositions of etoricoxib
WO2014201016A3 (en) Inhibitors of the mitf molecular pathway
UA109793C2 (uk) Арилсульфонаміди для лікування захворювань центральної нервової системи (цнс)
MX2015008292A (es) Derivados de naftiridinona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.
WO2013175359A3 (en) Compositions and methods for the treatment of multiple sclerosis
NZ707832A (en) 2-pyridone compound
MX360889B (es) Forma cristalina de un compuesto usado como un antagonista del receptor mineralocorticoide y metodo de preparacion de la misma.
WO2017085733A3 (en) Analgesic lipoic acid derivatives and the preparation thereof
WO2014060942A3 (en) Compositions and methods of for the treatment of multiple sclerosis and neurodegenerative diseases
CR20200565A (es) Coposiciones antimicrobianas con agentes efervescentes (divisional exp. 2016-0592)

Legal Events

Date Code Title Description
PSEA Patent sealed
LAPS Patent lapsed